BCC Research Bitopertin® Forecast

Report Highlights

With BCC Research's Bitopertin® Forecast, you will have quantitative data about forecasted revenue for the pharmaceutical drug bitopertin®, currently in development, that will guide you in your strategic decision-making regarding future participation in this product sector.

The BCC Research Bitopertin® Forecast is a quantitative forecast model in an easily accessible Microsoft® Excel® spreadsheet, segmented by specific parameters. It features:

• Market demand forecasts for Bitopertin® annually for the years 2016 to 2030 by volume (number of patients) and value (in U.S. dollars), should the drug be licensed

• Segmentation of volume and value for these regions:
   • United States
   • Japan
   • France
   • Germany
   • Italy
   • Spain
   • United Kingdom

• Data transparency and sources disclosed for:
   • Patient volumes, with forecasts by age range and prevalence, as well as population estimates
   • Product pricing forecasts


Use the BCC Research Bitopertin® Forecast to:
• Examine forecasted market demand for Bitopertin®
• Validate other Bitopertin® market-demand data to which you have access
• Make strategic decisions about entering Bitopertin®-related or schizophrenia treatment-related markets

Bitopertin® is a drug under development intended to be used in combination with antipsychotic medications for the treatment of persistent negative symptoms or sub-optimally controlled positive symptoms associated with schizophrenia.

 

Figure 1 Summary Graphs - Value in U.S.D. and Patient Volumes, by Region, 2016-2030

Table 1 Total Market - Value in U.S.D. and Patient Volumes, by Region, 2016-2030

Table 2 United States Patient Volumes, 2010-2030

Table 3 Japan Patient Volumes, 2010-2030

Table 4 France Patient Volumes, 2010-2030

Table 5 Germany Patient Volumes, 2010-2030

Table 6 Italy Volumes, 2010-2030

Table 7 Spain Patient Volumes, 2010-2030

Table 8 UK Patient Volumes, 2010-2030

Table 9 United States Population by age range, 2010-2012; and 2015 to 2060

Table 10 Europe Population by Country, 2010-2030

Table 11 Japan Population, 2010-2030

Table 12 US Pricing and FX Rate, 2016-2030

Table 13 Japan Pricing and FX rate, 2016-2030

Table 14 France Pricing and FX rate, 2016-2030

Table 15 Germany Pricing and FX rate, 2016-2030

Table 16 Italy Pricing and FX rate, 2016-2030

Table 17 Spain Pricing and FX rate, 2016-2030

Table 18 UK Pricing and FX rate, 2016-2030

Analyst Credentials

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.